Last reviewed · How we verify
SKYVaricella®
SKYVaricella® is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection.
SKYVaricella® is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection. Used for Prevention of varicella (chickenpox) in children and adults.
At a glance
| Generic name | SKYVaricella® |
|---|---|
| Sponsor | SK Bioscience Co., Ltd. |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a weakened form of the varicella-zoster virus that replicates in the body at a limited level, triggering both cellular and humoral immune responses without causing clinical disease. This primes the immune system to recognize and rapidly eliminate wild-type varicella-zoster virus upon natural exposure, preventing or significantly reducing the severity of chickenpox infection.
Approved indications
- Prevention of varicella (chickenpox) in children and adults
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Myalgia
Key clinical trials
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SKYVaricella® CI brief — competitive landscape report
- SKYVaricella® updates RSS · CI watch RSS
- SK Bioscience Co., Ltd. portfolio CI